Literature DB >> 3662471

Altered pharmacokinetic disposition of ciprofloxacin and vancomycin after single and multiple doses in rabbits.

S L Barriere1, G W Kaatz, D R Schaberg, R Fekety.   

Abstract

The pharmacokinetic disposition of vancomycin and ciprofloxacin was assessed in rabbits before the efficacy of these compounds in experimental staphylococcal endocarditis was compared. Ciprofloxacin was given in single intravenous bolus doses of 25 and 35 mg/kg and also in a multiple-dose regimen of 35 mg/kg every 6 h. Vancomycin was given in a similar manner in single doses of 17.5 and 25 mg/kg and in a multiple-dose regimen of 17.5 mg/kg every 6 h. Serum was sampled frequently after injections and analyzed by microbiologic assay for drug concentration. The pharmacokinetic parameters of clearance and steady-state volume of distribution were calculated by compartment-independent methods. These studies revealed that clearance of ciprofloxacin was reduced significantly after multiple doses (7.42 +/- 0.85 [standard deviation] versus 6.09 +/- 0.71 liters/h, P less than 0.01). Although the half-life and volume of distribution increased after multiple dosing, the differences were not statistically significant. The disposition of vancomycin following single doses was significantly altered after the 25-mg/kg dose compared with the 17.5-mg/kg dose. Half-life, clearance, and volume of distribution changed from 1.27 +/- 0.2 to 1.60 +/- 0.21 h (P less than 0.05), 0.54 +/- 0.05 to 0.39 +/- 0.04 liters/h (P less than 0.01), and 0.37 +/- 0.04 to 0.31 +/- 0.03 liters/kg (P less than 0.05), respectively. The disposition of ciprofloxacin was not altered with increases in dose size, and the disposition of vancomycin was not altered after multiple doses. If such alterations in the pharmacokinetic disposition of antimicrobial agents are unanticipated, the higher and more prolonged than expected serum concentrations may have an effect on the outcome of experimental infections.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3662471      PMCID: PMC174874          DOI: 10.1128/AAC.31.7.1075

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

2.  Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers.

Authors:  W Brumfitt; I Franklin; D Grady; J M Hamilton-Miller; A Iliffe
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

3.  Pharmacokinetics of intravenously administered ciprofloxacin.

Authors:  R Wise; R M Lockley; M Webberly; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

4.  Rapid microassay of gentamicin, kanamycin, neomycin, streptomycin, and vancomycin in serum or plasma.

Authors:  L D Sabath; J I Casey; P A Ruch; L L Stumpf; M Finland
Journal:  J Lab Clin Med       Date:  1971-09

5.  Multiple-dose ciprofloxacin kinetics in normal subjects.

Authors:  G E Aronoff; C H Kenner; R S Sloan; S T Pottratz
Journal:  Clin Pharmacol Ther       Date:  1984-09       Impact factor: 6.875

6.  In-vitro studies with ciprofloxacin, a new 4-quinolone compound.

Authors:  D S Reeves; M J Bywater; H A Holt; L O White
Journal:  J Antimicrob Chemother       Date:  1984-04       Impact factor: 5.790

7.  Multiple-dose ciprofloxacin dose ranging and kinetics.

Authors:  M A Gonzalez; A H Moranchel; S Duran; A Pichardo; J L Magana; B Painter; G L Drusano
Journal:  Clin Pharmacol Ther       Date:  1985-06       Impact factor: 6.875

8.  Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa.

Authors:  C W Norden; E Shinners
Journal:  J Infect Dis       Date:  1985-02       Impact factor: 5.226

9.  Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations.

Authors:  A S Bayer; K Lam
Journal:  J Infect Dis       Date:  1985-01       Impact factor: 5.226

10.  Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus.

Authors:  T C Carpenter; C J Hackbarth; H F Chambers; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

View more
  4 in total

1.  Enhanced elimination of ciprofloxacin after multiple-dose administration of rifampin to rabbits.

Authors:  S L Barriere; G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

2.  Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; S L Barriere; L M Albrecht; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

3.  Disposition kinetics and urinary excretion of ciprofloxacin in goats following single intravenous administration.

Authors:  R Raina; S Prawez; D J Dimitrova; N K Pankaj; P K Verma
Journal:  J Vet Sci       Date:  2008-09       Impact factor: 1.672

Review 4.  Development of Liposomal Ciprofloxacin to Treat Lung Infections.

Authors:  David Cipolla; Jim Blanchard; Igor Gonda
Journal:  Pharmaceutics       Date:  2016-03-01       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.